Acura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference

PALATINE, Ill., Aug. 31, 2017 -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that Bob Jones, President and Chief Executive Officer, will present at the 19^th Annual Rodman & Renshaw Global Investment Conference on Monday, September 11, 2017 at 1:45 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel, New York, NY.

The presentation, including previously unreleased clinical data on the Company’s LIMITx™ oral abuse deterrent technology, will be webcast live and may be accessed by visiting Acura’s website at www.acurapharm.com.  A replay of the webcast will be available for 90 days.

About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITx™, AVERSION® and IMPEDE® Technologies. LIMITx contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted.  IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

OXAYDO® (oxycodone HCl immediate-release tablets) which incorporates the AVERSION Technology, is FDA approved and marketed in the U.S. by our partner Egalet Corporation.

NEXAFED® and NEXAFED® Sinus, which are pseudoephedrine containing products that utilize the IMPEDE Technology, are marketed in the U.S. by our partner MainPointe Pharmaceuticals LLC.

Contact: 
for Acura Investor Relations
[email protected] 
847-705-7709